Zobrazeno 1 - 10
of 712
pro vyhledávání: '"B, De Groot"'
Autor:
J. C. Janssen, B. van Dijk, K. de Joode, M. J. B. Aarts, F. W. P. J. van den Berkmortel, C. U. Blank, M. J. Boers-Sonderen, A. J. M. van den Eertwegh, J. W. B. de Groot, M. Jalving, M. J. A. de Jonge, A. Joosse, E. Kapiteijn, A. M. Kamphuis-Huismans, K. A. T. Naipal, D. Piersma, B. Rikhof, H. M. Westgeest, G. Vreugdenhil, E. Oomen-de Hoop, E. E. A. P. Mulder, Astrid A. M. van der Veldt
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-7 (2024)
Abstract Background Patients with irresectable stage III or metastatic melanoma presenting with poor prognostic factors are usually treated with a combination of immune checkpoint inhibitors (ICIs), consisting of ipilimumab and nivolumab. This combin
Externí odkaz:
https://doaj.org/article/ca4c9e5c51fc40759d196932967e286e
Autor:
Lindsay V. M. Leek, Jessica C. L. Notohardjo, Karlijn de Joode, Eline L. Velker, John B. A. G. Haanen, Karijn P. M. Suijkerbuijk, Maureen J. B. Aarts, Jan Willem B. de Groot, Ellen Kapiteijn, Franchette W. P. J. van den Berkmortel, Hans M. Westgeest, Tanja D. de Gruijl, Valesca P. Retel, Edwin Cuppen, Astrid A. M. van der Veldt, Mariette Labots, Emile E. Voest, Joris van de Haar, Alfons J. M. van den Eertwegh
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract We evaluated the prognostic value of hypoalbuminemia in context of various biomarkers at baseline, including clinical, genomic, transcriptomic, and blood-based markers, in patients with metastatic melanoma treated with anti-PD-1 monotherapy
Externí odkaz:
https://doaj.org/article/0b86698c5e3b43c28f9ef4dd875f5025
Autor:
Kalijn F. Bol, Gerty Schreibelt, Martine Bloemendal, Wouter W. van Willigen, Simone Hins-de Bree, Anna L. de Goede, Annemiek J. de Boer, Kevin J. H. Bos, Tjitske Duiveman-de Boer, Michel A. M. Olde Nordkamp, Tom G. M. van Oorschot, Carlijn J. Popelier, Jeanne M. Pots, Nicole M. Scharenborg, Mandy W. M. M. van de Rakt, Valeska de Ruiter, Wilmy S. van Meeteren, Michelle M. van Rossum, Sandra J. Croockewit, Bouke J. Koeneman, Jeroen H. A. Creemers, Inge M. N. Wortel, Caroline Angerer, Mareke Brüning, Katja Petry, Andrzej Dzionek, Astrid A. van der Veldt, Dirk J. van Grünhagen, Johanna E. M. Werner, Johannes J. Bonenkamp, John B. A. G. Haanen, Marye J. Boers-Sonderen, Rutger H. T. Koornstra, Martijn F. Boomsma, Erik H. J. Aarntzen, Martin Gotthardt, James Nagarajah, Theo J. M. de Witte, Carl G. Figdor, Johannes H. W. de Wilt, Johannes Textor, Jan Willem B. de Groot, Winald R. Gerritsen, I. Jolanda M. de Vries
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-10 (2024)
Abstract Autologous natural dendritic cells (nDCs) treatment can induce tumor-specific immune responses and clinical responses in cancer patients. In this phase III clinical trial (NCT02993315), 148 patients with resected stage IIIB/C melanoma were r
Externí odkaz:
https://doaj.org/article/245269452ff04a81b46a9a6846fb6516
Autor:
M. Ghariq, W. B. van den Hout, O. M. Dekkers, M. Bootsma, B. de Groot, J. G. J. Groothuis, M. P. M. Harms, M. E. W. Hemels, E. C. A. Kaal, E. M. Koomen, F. J. de Lange, S. Y. G. Peeters, I. A. van Rossum, J. H. W. Rutten, E. W. van Zwet, J. G. van Dijk, R. D. Thijs, on behalf of the SYNERGY Consortium
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-15 (2023)
Abstract Background Syncope management is fraught with unnecessary tests and frequent failure to establish a diagnosis. We evaluated the potential of implementing the 2018 European Society of Cardiology (ESC) Syncope Guidelines regarding diagnostic y
Externí odkaz:
https://doaj.org/article/d5f9c4ecf56944c49da5af0c4bdfd679
Autor:
J. L. van Dam, E. M. M. Verkolf, E. N. Dekker, B. A. Bonsing, S. O. Bratlie, L. A. A. Brosens, O. R. Busch, L. M. J. W. van Driel, C. H. J. van Eijck, S. Feshtali, P. Ghorbani, D. J. A. de Groot, J. W. B. de Groot, B. C. M. Haberkorn, I. H. de Hingh, B. van der Holt, T. M. Karsten, M. B. van der Kolk, K. J. Labori, M. S. L. Liem, O. J. L. Loosveld, I. Q. Molenaar, M. B. Polée, H. C. van Santvoort, J. de Vos – Geelen, M. L. Wumkes, G. van Tienhoven, M. Y. V. Homs, M. G. Besselink, J. W. Wilmink, B. Groot Koerkamp, for the Dutch Pancreatic Cancer Group
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-8 (2023)
Abstract Background Surgical resection followed by adjuvant mFOLFIRINOX (5-fluorouracil with leucovorin, irinotecan, and oxaliplatin) is currently the standard of care for patients with resectable pancreatic cancer. The main concern regarding adjuvan
Externí odkaz:
https://doaj.org/article/9bd0b84a5c244ba18797a99563ce5af4
Autor:
Olivier J. van Not, Alfons J.M. van den Eertwegh, John B. Haanen, Christian U. Blank, Maureen J.B. Aarts, Jesper van Breeschoten, Franchette W.P.J. van den Berkmortel, Jan-Willem B. de Groot, Geke A.P. Hospers, Rawa K. Ismail, Ellen Kapiteijn, Manja Bloem, Melissa M. De Meza, Djura Piersma, Rozemarijn S. van Rijn, Marion A.M. Stevense-den Boer, Astrid A.M. van der Veldt, Gerard Vreugdenhil, Marye J. Boers-Sonderen, Willeke A.M. Blokx, Michel W.J.M. Wouters, Karijn P.M. Suijkerbuijk
Publikováno v:
EClinicalMedicine, Vol 69, Iss , Pp 102485- (2024)
Summary: Background: The prognosis of advanced melanoma patients has significantly improved over the years. We aimed to evaluate the survival per year of diagnosis. Methods: All systemically treated patients diagnosed with advanced melanoma from 2013
Externí odkaz:
https://doaj.org/article/09267a9e520444ec9384e855653228ee
Autor:
Birgit S. Geurts, Thomas W. Battaglia, J. Maxime van Berge Henegouwen, Laurien J. Zeverijn, Gijs F. de Wit, Louisa R. Hoes, Hanneke van der Wijngaart, Vincent van der Noort, Paul Roepman, Wendy W. J. de Leng, Anne M. L. Jansen, Frans L. Opdam, Maja J. A. de Jonge, Geert A. Cirkel, Mariette Labots, Ann Hoeben, Emile D. Kerver, Adriaan D. Bins, Frans G.L. Erdkamp, Johan M. van Rooijen, Danny Houtsma, Mathijs P. Hendriks, Jan-Willem B. de Groot, Henk M. W. Verheul, Hans Gelderblom, Emile E. Voest
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-14 (2023)
Abstract Background In this study we aimed to evaluate the efficacy and safety of the PD-L1 inhibitor durvalumab across various mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) tumours in the Drug Rediscovery Protocol (DRUP
Externí odkaz:
https://doaj.org/article/0e6af27c660548eab8d0d86d81fe251d
Autor:
K. van den Berg, D. P. Schaap, E. L. K. Voogt, T. E. Buffart, H. M. W. Verheul, J. W. B. de Groot, C. Verhoef, J. Melenhorst, J. M. L. Roodhart, J. H. W. de Wilt, H. L. van Westreenen, A. G. J. Aalbers, M. van ‘t Veer, C. A. M. Marijnen, J. Vincent, L. H. J. Simkens, N. A. J. B. Peters, M. Berbée, I. M. Werter, P. Snaebjornsson, H. M. U. Peulen, I. G. van Lijnschoten, M. J. Roef, G. A. P. Nieuwenhuijzen, J. G. Bloemen, J. M. W. E. Willems, G. J. M. Creemers, J. Nederend, H. J. T. Rutten, J. W. A. Burger
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background The presence of mesorectal fascia (MRF) invasion, grade 4 extramural venous invasion (EMVI), tumour deposits (TD) or extensive or bilateral extramesorectal (lateral) lymph nodes (LLN) on MRI has been suggested to identify patients
Externí odkaz:
https://doaj.org/article/f7aba25b45ad4d6685361c2d2a075b23
Autor:
Annegien Broeks, Sofie Wilgenhof, John B A G Haanen, Karolina Sikorska, Christian U Blank, Judith M Versluis, Jan Willem B de Groot, Esmee P Hoefsmit, Elisa A Rozeman, Petros Dimitriadis, Aysegul Sari, Daan van den Broek, Disha Rao, Ruben Lacroix, Lindsay G Grijpink-Ongering, Marta Lopez-Yurda, Birthe C Heeres, Bart A van de Wiel, Claudie Flohil, Stijn W T P J Heijmink, Marieke A Vollebergh, Johannes V van Thienen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 7 (2023)
Background Continuous combination of MAPK pathway inhibition (MAPKi) and anti-programmed death-(ligand) 1 (PD-(L)1) showed high response rates, but only limited improvement in progression-free survival (PFS) at the cost of a high frequency of treatme
Externí odkaz:
https://doaj.org/article/85f4bb454d4548b7b0eddc4aff9da5e2
Autor:
M. S. Walma, S. J. Rombouts, L. J. H. Brada, I. H. Borel Rinkes, K. Bosscha, R. C. Bruijnen, O. R. Busch, G. J. Creemers, F. Daams, R. M. van Dam, O. M. van Delden, S. Festen, P. Ghorbani, D. J. de Groot, J. W. B. de Groot, N. Haj Mohammad, R. van Hillegersberg, I. H. de Hingh, M. D’Hondt, E. D. Kerver, M. S. van Leeuwen, M. S. Liem, K. P. van Lienden, M. Los, V. E. de Meijer, M. R. Meijerink, L. J. Mekenkamp, C. Y. Nio, I. Oulad Abdennabi, E. Pando, G. A. Patijn, M. B. Polée, J. F. Pruijt, G. Roeyen, J. A. Ropela, M. W. J. Stommel, J. de Vos-Geelen, J. J. de Vries, E. M. van der Waal, F. J. Wessels, J. W. Wilmink, H. C. van Santvoort, M. G. Besselink, I. Q. Molenaar, for the Dutch Pancreatic Cancer Group
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-12 (2021)
Abstract Background Approximately 80% of patients with locally advanced pancreatic cancer (LAPC) are treated with chemotherapy, of whom approximately 10% undergo a resection. Cohort studies investigating local tumor ablation with radiofrequency ablat
Externí odkaz:
https://doaj.org/article/3d301f6bd2bd4bac89f7f45ee7d3f040